Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · KILITCH

KILITCH DRUG

HealthcarePharmaceuticals & Biotechnology₹807 cr market cap
₹234.00 ▲ +1.69% today As of 19 Nov 2026
52-week low ₹124.4552-week high ₹260.70

-11.7% from the 52-week high · +84.9% above the low

Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products portfolio includes Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and many other areas in the form of ampoules and vials. The Company’s range of oral formulations includes tablets, capsules, dry syrups and oral powders. The Company’s medical devices offer a C-Seal brand. The company has a range of cosmetics ranging from oil, lotion and liquid to cream and paste in skin care, personal care, and hair care category. The firm has its manufacturing units located in India and Ethiopia.

The short version. KILITCH DRUG reported revenue of ₹50 crore for Sep 2026, up 2.0% from a year earlier. Net profit was ₹2 crore (down 75.0% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 63.77% in Sep 2026, down 5.46 points over 8 quarters.

1 · The price

How has the stock traded?

KILITCH DRUG trades 11.7% below its 52-week high and 84.9% above its 52-week low.

Change over period: —

1M+5.1%
3M+45.6%
6M+25.2%
1Y+29.5%

2 · The business

Is it growing?

Sales, year on year+2.0%

Sep 2026 revenue of ₹50 cr.

Profit, year on year-75.0%

Sep 2026 net profit of ₹2 cr.

Net margin4.4%

12.3 pts lower than a year earlier.

3-year growth42.4% profit

Revenue compounded at 20.1% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5045905449436156
Net profit2315483106
Net margin %4.46.516.28.216.77.017.010.6
EPS (₹)0.640.834.151.272.340.872.971.7

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue235198154140114695382
Net profit302715107414
Net margin %12.813.59.57.56.45.41.64.6
EPS (₹)8.637.644.183.082.171.090.251.15

3 · The quality

How well does it turn capital into profit?

Return on equity was 10.8% in Mar 2026; debt to equity is 0.32.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %10.813.28.36.9
Return on capital %13.217.314.411.2
EBITDA margin %19.420.318.014.4
Net margin %12.212.89.27.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR20.1%28.2%
Profit CAGR42.4%52.4%
Debt to equity0.32
Interest cover8.0x
Current ratio1.83
P/E ratio33.6

4 · The owners

Who holds it, and are they adding?

Promoter holding63.77%

Down 5.46 pts over 8 quarters.

Foreign institutions0.11%

Up 0.11 pts over 8 quarters.

Domestic institutions0.5%

Up 0.5 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter69.2369.2369.2363.7763.7763.7763.7763.77-5.46
FII0000000.120.11+0.11
DII00000000.5+0.5
Public30.7730.7730.7636.2336.2336.2236.1135.62+4.85

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.01% of NAV
  • Bandhan BSE Healthcare Index Fund0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for KILITCH DRUG are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about KILITCH DRUG

What is the KILITCH DRUG share price?

KILITCH DRUG (KILITCH) last closed at ₹234.00, up 1.69% on the day. Its 52-week range is ₹124.45 to ₹260.70.

What is the market cap of KILITCH DRUG?

KILITCH DRUG has a market capitalisation of about ₹807 crore. Its price-to-earnings ratio is 33.6.

How are KILITCH DRUG's latest results?

KILITCH DRUG reported revenue of ₹50 crore for Sep 2026, up 2.0% from a year earlier. Net profit was ₹2 crore (down 75.0% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 63.77% in Sep 2026, down 5.46 points over 8 quarters.

Who owns KILITCH DRUG?

As of Sep 2026, shareholding was: Promoter 63.77%, FII 0.11%, DII 0.5%, Public 35.62%.

How many mutual funds hold KILITCH DRUG?

2 mutual fund schemes held KILITCH DRUG in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 24 Mar 2026 · Bonus issue 1:1
  • 15 Jul 2025 · Rights issue 2:23
  • 20 Sep 2019 · Final Dividend - Rs. 0.5
  • 18 Sep 2018 · Final Dividend - Rs. 0.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.